Cargando…
Small-Molecule Targets in Tumor Immunotherapy
Cancer immunotherapy has been widely recognized as a powerful approach to fight cancers. To date, over 50 phase III trials in cancer immunotherapy are in progress. Among the many immunotherapy approaches, immune checkpoint therapy has attracted considerable attention. The reported clinical success o...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102179/ https://www.ncbi.nlm.nih.gov/pubmed/29974338 http://dx.doi.org/10.1007/s13659-018-0177-7 |
_version_ | 1783349105662099456 |
---|---|
author | Zhu, Hui-Fang Li, Yan |
author_facet | Zhu, Hui-Fang Li, Yan |
author_sort | Zhu, Hui-Fang |
collection | PubMed |
description | Cancer immunotherapy has been widely recognized as a powerful approach to fight cancers. To date, over 50 phase III trials in cancer immunotherapy are in progress. Among the many immunotherapy approaches, immune checkpoint therapy has attracted considerable attention. The reported clinical success of targeting the T cell immune checkpoint receptors PD-1 or CTLA4 by antibodies blockade in advanced stages of cancers has demonstrated the importance of immune modulation. But antibodies-based immunotherapy confronted with some disadvantages, such as immunogenicity, stability, membrane permeability, and production cost. Therefore, alternative approaches including small-molecule-regulated immune response are being introduced. In this review, we focused on some of the key intracellular pathways where small-molecule therapeutic is potential and attractive, which highlights the great potential of natural products in this field. |
format | Online Article Text |
id | pubmed-6102179 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-61021792018-08-27 Small-Molecule Targets in Tumor Immunotherapy Zhu, Hui-Fang Li, Yan Nat Prod Bioprospect Review Cancer immunotherapy has been widely recognized as a powerful approach to fight cancers. To date, over 50 phase III trials in cancer immunotherapy are in progress. Among the many immunotherapy approaches, immune checkpoint therapy has attracted considerable attention. The reported clinical success of targeting the T cell immune checkpoint receptors PD-1 or CTLA4 by antibodies blockade in advanced stages of cancers has demonstrated the importance of immune modulation. But antibodies-based immunotherapy confronted with some disadvantages, such as immunogenicity, stability, membrane permeability, and production cost. Therefore, alternative approaches including small-molecule-regulated immune response are being introduced. In this review, we focused on some of the key intracellular pathways where small-molecule therapeutic is potential and attractive, which highlights the great potential of natural products in this field. Springer Singapore 2018-07-05 /pmc/articles/PMC6102179/ /pubmed/29974338 http://dx.doi.org/10.1007/s13659-018-0177-7 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Zhu, Hui-Fang Li, Yan Small-Molecule Targets in Tumor Immunotherapy |
title | Small-Molecule Targets in Tumor Immunotherapy |
title_full | Small-Molecule Targets in Tumor Immunotherapy |
title_fullStr | Small-Molecule Targets in Tumor Immunotherapy |
title_full_unstemmed | Small-Molecule Targets in Tumor Immunotherapy |
title_short | Small-Molecule Targets in Tumor Immunotherapy |
title_sort | small-molecule targets in tumor immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102179/ https://www.ncbi.nlm.nih.gov/pubmed/29974338 http://dx.doi.org/10.1007/s13659-018-0177-7 |
work_keys_str_mv | AT zhuhuifang smallmoleculetargetsintumorimmunotherapy AT liyan smallmoleculetargetsintumorimmunotherapy |